Cite
HARVARD Citation
Mahomed, S. et al. (2023). Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trial. Lancet. 10 (4), pp. e230-e243. [Online].